The Research

This randomized, double-blind, placebo-controlled study assessed whether extended use of oxymetazoline nasal spray—typically cautioned against due to risks of rebound congestion and tachyphylaxis—would actually produce such effects in healthy individuals. Subjects received 0.05% oxymetazoline nasal spray three times daily for four weeks, and were monitored during and after treatment for nasal blockage and decongestant responsiveness.

This randomized, double-blind, placebo-controlled study investigated how different doses of intranasal oxymetazoline impact nasal airflow and congestion symptoms in healthy adults without nasal obstruction. Researchers assessed nasal airway resistance (NAR), total minimum cross-sectional area (tMCA), total nasal volume (tVOL), and perceived congestion.

This study examined the impact of a topical decongestant on nasal mucosal blood flow in both healthy individuals and those with early-stage acute rhinitis. Using the 133Xe wash-out method, researchers measured blood flow before and after administering the decongestant. Researchers measured changes in blood flow following the application of various doses of oxymetazoline.